Gene
CDKN1B
cyclin dependent kinase inhibitor 1B
Explore in graph →CI-GENE-00040776HGNC:1785 ENSG00000111276 NCBI 1027 CIViC Cancer geneApproved
Curated evidence
Clinical evidence (2)
CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 25587029
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| CDKN1B CYTOPLASMIC MISLOCALIZATION1 | ||||||||
| Lapatinib | Malignant Breast Neoplasm | Predictive | D | Supports Resistance | 3 | accepted | EID860Cytoplasmic localization of p27 (CDKN1B) leads to lapatinib resistance in HER2+ breast cancer cell lines. p27 knockout resensitiuzed cells to lapatinib. PMID 25587029 · Zhao et al., 2014 · Open in CIViC | civic |
| CDKN1B EXPRESSION1 | ||||||||
| Cisplatin + FluorouracilCombination | Head and Neck Squamous Cell Carcinoma | Predictive | B | Supports Sensitivity Response | 2 | accepted | EID88941 HNSSC were analyzed by IHC for expression of EGFR, p53, CCND1, p16, p21, p27 (CDKN2B), p-AKT, HIF-1a, Caspase 3 and BCL2. p27 was the only protein that served as a predictive biomarker of response … | |
Cohorts
Alteration frequency by cohort (72)
Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.
- Source
- cBioPortal for Cancer Genomics (public studies)
- Dataset
- cBioPortal mutated genes by study
- Version
- cbioportal-2026-09-01
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- cohort
- License
- ODC Open Database License (ODC-ODbL) unless otherwise noted per study; attribution to the original studies required
- PMID
- 32317181
- Run
- ING-CBIOPORTAL-20260908-000001
| Cohort | Mapped cancer | Alteration | Affected (n) | Profiled (n) | Frequency (%) | Rank in cohort | Source |
|---|---|---|---|---|---|---|---|
| Prostate Adenocarcinoma (MSK, Eur Urol 2020) prad_cdk12_mskcc_2020 | Prostate Adenocarcinoma | Ssm | 15 |
Literature
Linked publications (2)
25 per page, newest first.
- Source
- PubMed (NLM)
- Dataset
- PubMed E-utilities
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- p27 and BCL2 expression predicts response to chemotherapy in head and neck squamous cell carcinomas.
· Oral Oncol · 2014 · PMID 24239278 · validated civic_curation pubmed
· Oncotarget · 2014 · PMID 25587029 · validated civic_curation pubmed